Comparing drug-resistant epilepsy treatments: medicines, resection, ablation, stimulation, and dietary therapy

Begin by establishing which options are feasible for the individual. A safely treatable focal region, a widespread seizure network, a particular childhood syndrome, and severe medication intolerance create different decisions. A universal ranking of treatments overlooks these conditions. Comprehensive evaluation should narrow the comparison to approaches supported by the patient's own evidence. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022Scheffer et al.: ILAE classification of the epilepsies, 2017

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Sustained seizure freedom, a halving of frequency, fewer falls, shorter recovery, and fewer medicines are different outcomes. A reduction percentage is not the same as the proportion of patients without any seizures. Memory, alertness, and independence may also be central to the patient's decision and should be included explicitly. Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019 NINDS: Epilepsy and Seizures
The SANTE follow-up and nine-year responsive-neurostimulation study describe outcomes and safety during continuing treatment in selected focal-epilepsy populations. Their later phases were not permanently maintained randomized comparisons. Medicines, parameters, and the group remaining under observation could change. Salanova et al.: SANTE long-term thalamic stimulation study, Epilepsia 2021 Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020
A practical comparison sheet can list each option's objective, supporting patient evidence, major risks, continuing tasks, uncertainty, and responsible clinician. Explain which potential consequences are hardest to accept, such as meaningful language loss, repeated distant visits, or an unsustainable diet. The team can then discuss tradeoffs in terms that matter to the patient.

Quick answer

Begin by establishing which options are feasible for the individual. A safely treatable focal region, a widespread seizure network, a particular childhood syndrome, and severe medication intolerance create different decisions. A universal ranking of treatments overlooks these conditions. Comprehensive evaluation should narrow the comparison to approaches supported by the patient's own evidence. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Scheffer et al.: ILAE classification of the epilepsies, 2017

Full guide

Begin by establishing which options are feasible for the individual. A safely treatable focal region, a widespread seizure network, a particular childhood syndrome, and severe medication intolerance create different decisions. A universal ranking of treatments overlooks these conditions. Comprehensive evaluation should narrow the comparison to approaches supported by the patient's own evidence. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Scheffer et al.: ILAE classification of the epilepsies, 2017

Choose the outcome being compared

Sustained seizure freedom, a halving of frequency, fewer falls, shorter recovery, and fewer medicines are different outcomes. A reduction percentage is not the same as the proportion of patients without any seizures. Memory, alertness, and independence may also be central to the patient's decision and should be included explicitly. Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019 NINDS: Epilepsy and Seizures

Ask what each option mainly aims to improve, when that effect will be reviewed, and what happens if it is insufficient. A realistic prospect of complete control and an aim of reducing burden should be distinguished. An approach focused on burden reduction can still be valuable for someone whose other options are limited.

Medicines allow adjustment but require continuing exposure

Rational medication selection or combination can still improve control, particularly when classification, actual use, or interactions leave something correctable. Medicines generally avoid an intracranial procedure but require continuing assessment of adverse effects, cognition, mood, and organ safety. Adjustability does not mean that patients can start or stop them without guidance. NICE NG217: Principles of treatment, safety, monitoring and withdrawal Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26

When comparing regimens, ask whether each covers the main event types, adds redundant adverse effects, and can be used reliably. A high response in a new-drug study may reflect a particular population, dose, and observation period. It cannot be directly subtracted from a hospital's postoperative result to produce an individual advantage.

Resection depends on an acceptable treatment target

For appropriately selected focal epilepsy, surgery can offer a meaningful opportunity for seizure freedom. Localization and assessment of language, memory, movement, visual fields, and other risks are prerequisites. An abnormality on MRI alone does not justify a promise that removal will certainly resolve epilepsy. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

The classic randomized temporal-lobe epilepsy trial supports surgery over continued medication for the selected population studied. It does not establish the same conclusion for every drug-resistant epilepsy. Different localization, causes, and functional risks require a return to the patient's own evidence. Wiebe et al.: Randomized trial of surgery for temporal-lobe epilepsy, NEJM 2001

Ask how closely your case resembles the group supporting the recommendation. The relevant match includes the seizure network and proposed procedure, not simply the shared word refractory in the diagnosis. Outcomes should also include complications and continuing treatment requirements.

Early surgery evidence answers a specific question

ERSET compared surgery plus medication with continued medication in recently drug-resistant mesial temporal lobe epilepsy after a standardized assessment established suitability for the proposed resection. The trial supports timely surgical consideration in that selected setting. Its small sample, early termination for slow recruitment, and treatment crossover are relevant limitations. Engel et al.: Early surgery versus medical treatment for drug-resistant MTLE, randomized trial, JAMA 2012

It helps answer whether suitable patients should continue medication trials indefinitely. It does not show that every epilepsy should be resected, nor does freedom from disabling seizures mean that everyone stopped medication or remained free of every minor event permanently. The definition and follow-up period matter to interpretation.

Laser ablation is less invasive at the entry site but still treats brain tissue

Laser interstitial thermal therapy may be appropriate for selected focal or deep targets. Its access and recovery differ from open resection, but treatment extent, nearby function, hemorrhage, and other risks still require discussion. A smaller skin opening does not independently establish a better option or guarantee the absence of cognitive effects. NINDS: Epilepsy and Seizures

The prospective LAANTERN registry publication in 2025 provides follow-up information for mesial temporal epilepsy treated with LITT. As a registry cohort, it is not a randomized comparison against contemporary open surgery. It can inform discussion of observed outcomes and treatment experience but cannot alone establish universal superiority of ablation. Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy, prospective LAANTERN registry, JAMA Neurology 2025

If both approaches are plausible, ask about the target, expected control, functional risk, and what could follow if the first intervention were insufficient. The decision should be based on the whole procedure rather than the appeal of the word minimally invasive.

Disconnection procedures can have a different principal objective

Some patients lack a single suitable focal resection target or have a more extensive network. Callosotomy or another disconnection strategy may be considered to reduce particular seizure propagation or dangerous falls. The relevant population, functional assessment, and intended benefit differ from removal of one localized lesion. NINDS: Epilepsy and Seizures

Ask which events may improve and which may remain, together with recovery and rehabilitation needs. Preventing severe falls should not be described as eliminating every seizure. In children, families also need an explanation of possible effects on movement, learning, and day-to-day assistance.

Vagus nerve and intracranial stimulation are distinct approaches

Vagus nerve stimulation connects an implanted system to the cervical vagus nerve. Deep brain and responsive stimulation use different targets, implantation arrangements, and modes of operation. They may reduce seizure burden in suitable patients, generally alongside continued medication, programming, and device follow-up. NINDS: Deep Brain Stimulation NICE NG217: Full guideline, updated January 30, 2025

Verify the actual product's indication, age range, scanning conditions, and availability in the relevant country. Publication of China's 2026 neuromodulation guideline does not establish that every foreign system is commercially available in China on identical terms. The ability to obtain programming and troubleshoot problems after returning home belongs in the suitability assessment. 中华医学会：神经调控治疗癫痫临床指南2026版，中华医学杂志106(11)，期刊目录及摘要

An implanted device may change the organization of future care. Clarify the local clinician's access to the appropriate system and the treating center's responsibilities. A procedure performed successfully is only one stage of the continuing treatment.

Long-term stimulation results should not become a league table

The SANTE follow-up and nine-year responsive-neurostimulation study describe outcomes and safety during continuing treatment in selected focal-epilepsy populations. Their later phases were not permanently maintained randomized comparisons. Medicines, parameters, and the group remaining under observation could change. Salanova et al.: SANTE long-term thalamic stimulation study, Epilepsia 2021 Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020

It is inappropriate to compare separate long-term median reduction figures and conclude that one system must outperform another for an individual. A reduction in frequency is also different from the proportion ever experiencing a seizure-free interval. Consider entry criteria, follow-up completion, important adverse events, and continuing medication as well as the headline result.

Improvement over years can matter greatly to a patient. Acknowledging the design limitations does not dismiss that value; it defines what can reasonably be inferred. Ask the clinician how the evidence informs expectations for the specific proposed device and patient.

Dietary therapy requires a comparison of benefit and feasibility

Ketogenic or modified Atkins approaches may be considered following specialist assessment. Studies often add the diet to standard medication, so improvement cannot be interpreted as proof that food alone replaces all medicines. Nutrition, gastrointestinal effects, metabolic risks, and sustained household participation influence the decision. NICE NG217: Full guideline, updated January 30, 2025

A 2023 randomized study compared modified Atkins plus standard drugs with standard drugs in selected adolescent and adult drug-resistant epilepsy and evaluated outcomes at six months. It supports discussing dietary treatment in an appropriate setting. Its population and follow-up do not justify unsupervised long-term use of a recipe by every household. Manral et al.: Modified Atkins diet randomized trial in adolescent and adult DRE, Neurology 2023

Ask who will provide nutritional review and what happens if the proposed restrictions are not sustainable. A diet that cannot realistically be implemented should not be compared as though it will be followed perfectly. The patient's circumstances are part of the clinical choice.

Etiology-directed treatment needs a reliable diagnosis

Some genetic, metabolic, or immune conditions create options beyond ordinary seizure suppression. Their value depends on the actual cause and mechanism. The drug-resistant label alone does not indicate a targeted medicine or immunotherapy, and different variants within one gene can have different implications. Krey et al.: Current practice in diagnostic genetic testing of the epilepsies, ILAE Genetics Commission, 2022 Abboud et al.: Autoimmune encephalitis diagnosis and acute management best-practice recommendations, 2021

Ask whether the proposed treatment is intended to improve seizures, modify the underlying disorder, or address another feature. Clarify the evidence type. An early study may be relevant to research consideration but should not carry the same certainty as an established option. A research intervention also requires verification of the project and its follow-up responsibilities.

Include reversibility, recovery, and future choices

Medication adjustment, programming, tissue removal, and ablation differ in how they affect later options. Some parameters can be changed, whereas treated tissue cannot simply be restored. Understand what happens if benefit is insufficient and whether the first treatment affects the feasibility of a subsequent approach. NINDS: Epilepsy and Seizures

Compare more than the initial hospital stay. Consider recovery, reviews, readmission, rehabilitation, and long-term support. Surgery may be followed by continuing medication, and a device may require replacement or treatment of a complication. A fixed recovery promise should not be applied to every person or procedure.

Write down which uncertainties could materially change the choice. Some can be clarified before treatment; others remain inherent in the intervention. The decision is more transparent when these are acknowledged rather than hidden within a general success claim.

Avoid three common comparison errors

Do not rank percentages from unrelated studies, report only the best outcomes while omitting serious events and incomplete follow-up, or assume that the newest and most costly approach is automatically appropriate. First examine how closely the evidence population matches the patient, then compare equivalent outcomes over relevant periods. Engel et al.: Early surgery versus medical treatment for drug-resistant MTLE, randomized trial, JAMA 2012 Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020

If one study defines success as absence of disabling seizures during an observed interval and another requires absence of every seizure, the two percentages do not represent the same achievement. Ask the clinician to explain the definitions and separately address the events the patient most wants to prevent.

Turn a comparison into real options in China

A comprehensive epilepsy service should explain which approaches are feasible, which require more evidence, and which are currently inadvisable. CAAE center information can help locate an inquiry route, but confirm the actual team, technology, and continuing support. Listing a procedure on a promotional page does not establish suitability for every referred patient. 中国抗癫痫协会：第五批一、二级癫痫中心评审结果，2025年9月28日

Request an itemized estimate in renminbi for the proposed work, including monitoring, programming, medicines, and potentially additional treatment. Confirm costs and insurance eligibility separately. A foreign study's economic analysis is not a current Chinese quotation, and availability of a technology does not establish personal reimbursement. 国家医保局：2025年目录通知，2026年执行

Compare the complete care you would receive

A practical comparison sheet can list each option's objective, supporting patient evidence, major risks, continuing tasks, uncertainty, and responsible clinician. Explain which potential consequences are hardest to accept, such as meaningful language loss, repeated distant visits, or an unsustainable diet. The team can then discuss tradeoffs in terms that matter to the patient.

If evidence is insufficient, complete the investigations likely to change the choice while maintaining necessary care. Agreeing to evaluation does not commit the patient to an operation. Once a choice is made, identify the review point and how it can be revisited if new evidence or life circumstances change the balance.